OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances

OPKO HEALTH, INC.

2026-Q1 EPS reported -$0.07 revenue$124,196,000

Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).
Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.
Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.
Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.
FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.

Period: the three months ended March 31, 2026
Revenue: $124.2 million
Net income: $54.8 million
EPS: $0.07 per share
Result: reported results

Exact text from the filing

each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-186939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.